Phil Higdon

Horse racing enthusiast and small time investor.

[Phil Higdon @philbag84]

@Rik2273 So if they get that amount, then the 1000 vials ready for shipment is basically worth $35,800,000 in revenue ?? $IBRX

[Phil Higdon @philbag84]

Anyone know the market value of one vial of Anktiva ?? $IBRX

[Phil Higdon @philbag84]

@LoriMills4CA42 GREAT job today Lori. Hope your husband continues to be in good health !!! And THANK YOU for making the effort !!!

[Phil Higdon @philbag84]

@DrPatrick FDA is calling on patients, clinicians, and researchers to help identify drugs that could be repurposed to treat chronic and rare diseases and help address other unmet medical needs. Share your ideas to help advance new treatment options. https://t.co/kyiCW4BXqU

[Phil Higdon @philbag84]

@ImmunityBio FDA is calling on patients, clinicians, and researchers to help identify drugs that could be repurposed to treat chronic and rare diseases and help address other unmet medical needs. Share your ideas to help advance new treatment options. https://t.co/kyiCW4BXqU

[Phil Higdon @philbag84]

@DrMakaryFDA If the FDA has shifted to a higher gear then why hasnt it approved Anktiva for lymphopenia, and other indications besides bladder cancer?

[Phil Higdon @philbag84]

@ike0114 @DrPatrick @joerogan @US_FDA @DrMakaryFDA @realDonaldTrump @SusieWiles @DrPatrick Please consider going on the @joerogan podcast to discuss Anktiva, lymphopenia, etc.

[Cultura Literal @culturaliteral1]

Los caballos no sólo sienten tu tacto: sienten tu alma.

[Phil Higdon @philbag84]

@papapallad10904 SR is Special Report and PSS will be interviewed on it by Bret Baier tonight on Fox News at 6 pm EST

[Phil Higdon @philbag84]

@BretBaier What is SR ? And what time does it air?

[Phil Higdon @philbag84]

@VDHanson @DrPatrick Sir, I think you might look into getting Anktiva from Dr Patrick Soon Shiong of ImmunityBio. This drug enhances you immune system to produce cells that kill cancer, diseases, sepsis, etc.

[Phil Higdon @philbag84]

@JasonWitt_X @DrPatrick @ImmunityBio It has been resubmitted.

[IdenixHunter @IdenixH]

$IBRX Why is the RMAT designation for Reversal and Maintenance of Absolute Lymphocyte Counts such a big deal? Oncologists could begin using for all Tumor types immediately without getting individual approval for each type....and get it paid for.

[Bullish @bullishbruk]

$IBRX Dr. Patrick Soon-Shiong appears to indicate full support from the US President and government for the Cancer BioShield platform. This aligns with the recent US-Saudi Biotech Alliance Summit, where commitments advance BioShield partnerships—including military-aligned global health security efforts. It doesn’t get any clearer than that! It is shorts funeral! @DrPatrick Thank you! @Umbisam @LoriMills4CA42

[IdenixHunter @IdenixH]

$IBRX
New investor here but 32 years in Big Pharma (Oncology/Virology). The most exciting thing about IBRX is their RMAT Designation for Reversal of Lymphopenia and Pancreatic Cancer. We could see full FDA approval within 6 months of submission and the package can be based of Ph2

[Saisei @SaiseiInvesting]

$IBRX | @DrPatrick @ImmunityBio

“… Bladder cancer, lung cancer… the Saudis are committed to me for any other cancers because they want the data as well.

The Saudis want it not only for the nation but for all of the Middle East and all of Africa.

Saudi Arabia wants to make Healthcare part of GDP and I think this is where we are missing the boat as Americans.”

[Stonvex @petitnong_]

Let me explain the relationship between ImmunityBio's ANKTIVA and its other drug candidates in an easy-to-understand way.

$IBRX is utilizing ANKTIVA as a core "backbone," combining it with various other therapies in its pipeline.

By creating combinations such as ANKTIVA + hAd5, ANKTIVA + haNK, and ANKTIVA + CAR-NK, the company is expanding its reach far beyond bladder cancer. This strategic synergy targets a vast range of indications, including head and neck, cervical, anal, colorectal, lung, breast, and brain cancers, as well as B-cell lymphoma and ovarian cancer.

With ANKTIVA at the center of these combinations, we may soon see a world where there is no cancer that $IBRX cannot treat.

@DrPatrick @ImmunityBio

[Dr. Pat Soon-Shiong @DrPatrick]

The missing link. One of many episodes coming to explain the power of NK cells ..we will show patient videos as part of the discussions and see the impact it is making across all tumor types

[Phil Higdon @philbag84]

@NBSaphierMD @DrMarcSiegel below is link to IBRX's Anktiva in Glioblastoma https://t.co/iTS2tnN9Js